{
    "clinical_study": {
        "@rank": "151628", 
        "arm_group": {
            "arm_group_label": "Treatment (capecitabine, gefitinib)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive oral gefitinib once daily on days 1-14 and oral capecitabine twice daily on days 8-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gefitinib and capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial is studying the side effects and best dose of gefitinib and capecitabine\n      in treating patients with advanced solid tumors. Biological therapies such as gefitinib may\n      interfere with the growth of tumor cells and slow the growth of solid tumors. Drugs used in\n      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or\n      die. Combining gefitinib and capecitabine may kill more tumor cells"
        }, 
        "brief_title": "Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors", 
        "condition": "Unspecified Adult Solid Tumor, Protocol Specific", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the maximum tolerated dose of gefitinib and capecitabine in patients with\n      advanced solid tumors.\n\n      II. Determine the dose-limiting toxic effects of this regimen in these patients.\n\n      III. Determine the pharmacologic profile of this regimen in these patients.\n\n      OUTLINE: This is a dose-escalation study of gefitinib and capecitabine.\n\n      Patients receive oral gefitinib once daily on days 1-14 and oral capecitabine twice daily on\n      days 8-21. Treatment repeats every 28 days in the absence of disease progression or\n      unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gefitinib and\n      capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the\n      dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.\n\n      PROJECTED ACCRUAL: A total of 11-41 patients will be accrued for this study within 2.5\n      years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed advanced solid tumor that is refractory to standard therapy\n             or for which no standard therapy exists\n\n          -  No uncontrolled brain metastases, including symptomatic lesions or lesions requiring\n             treatment (e.g., glucocorticoids and/or anticonvulsants)\n\n          -  Performance status - ECOG 0-2\n\n          -  At least 12 weeks\n\n          -  WBC at least 3,000/mm^3\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n          -  Hemoglobin at least 9 g/dL\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n          -  AST and ALT no greater than 2.5 times upper limit of normal (5 times ULN if liver\n             metastases present)\n\n          -  Creatinine no greater than 1.5 mg/dL\n\n          -  Creatinine clearance at least 60 mL/min\n\n          -  No active infections\n\n          -  No other serious concurrent systemic disorders that would preclude study\n             participation\n\n          -  No other malignancy\n\n          -  No prior hypersensitivity to sulfonamide-based drugs, nonsteroidal anti-inflammatory\n             drugs, or fluorouracil\n\n          -  No documented dihydropyrimidine dehydrogenase deficiency\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  No concurrent immunotherapy\n\n          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and\n             recovered\n\n          -  No concurrent hormonal therapy\n\n          -  At least 28 days since prior radiotherapy\n\n          -  No concurrent radiotherapy\n\n          -  At least 4 weeks since prior investigational agents\n\n          -  No other concurrent experimental medications\n\n          -  No concurrent drugs known to induce cytochrome P450 3A4 (e.g., rifampin, phenytoin,\n             carbamazepine, or barbiturates)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 6, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00039390", 
            "org_study_id": "NCI-2012-02467", 
            "secondary_id": [
                "UCHSC-01479", 
                "U01CA099176", 
                "CDR0000069379"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (capecitabine, gefitinib)", 
                "description": "Given orally (PO)", 
                "intervention_name": "capecitabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CAPE", 
                    "Ro 09-1978/000", 
                    "Xeloda"
                ]
            }, 
            {
                "arm_group_label": "Treatment (capecitabine, gefitinib)", 
                "description": "Given PO", 
                "intervention_name": "gefitinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Iressa", 
                    "ZD 1839"
                ]
            }, 
            {
                "arm_group_label": "Treatment (capecitabine, gefitinib)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }, 
            {
                "arm_group_label": "Treatment (capecitabine, gefitinib)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Fluorouracil", 
                "Gefitinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Denver", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80217-3364"
                }, 
                "name": "University of Colorado"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Trial of ZD1839 With Capecitabine in Patients With Advanced Solid Tumors (Formerly a Phase I Trial of ZD1839 With Capecitabine and Celecoxib)", 
        "overall_official": {
            "affiliation": "University of Colorado, Denver", 
            "last_name": "Michele Basche", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum-tolerated dose (MTD) defined as the those below that results in dose-limiting toxicity (DLT) in >= 2 of 6 new patients, as assessed by CTCAE version 3.0", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "DTL defined as any grade 3 or greater non-hematological toxicity, and grade 3 or greater skin rash, grade 4 thrombocytopenia and/or neutropenia as assessed by CTCAE version 3.0", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Pharmacological profile", 
                "safety_issue": "No", 
                "time_frame": "At baseline, at 30 minutes, at 1, 2, 3, and 4 hours of days 8, 14, and 21 (course 1)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00039390"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "April 2002", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }, 
    "geocoordinates": {
        "University of Colorado": "39.739 -104.985"
    }
}